Dicerna begins Phase I trial of DCR-MYC to treat solid tumors, hematological malignancies..... AMRI realigns discovery and development services to support customer demand..... European Medicines Agency alerts EU healthcare professionals after vials of falsified Herceptin identified..... Astellas Pharma reaches agreement with US Department of Justice..... Apricus Biosciences' UK partner accepts first shipment of Vitaros..... Iconic Therapeutics raises $20m to advance clinical development of wet AMD program..... Top 10 M&A deals of 2013..... Medac Pharma gets FDA approval for trade name Rasuvo for injectable MTX product..... Prosonix, Mylan license agreement for generic versions of Flixotide and Flovent..... RainTree launches new cloud-based analytics portal for pharmaceutical industry..... Prestige to acquire OTC oral rehydration product Hydralyte in Australia..... DesignMedix gets $3m NIH grant to develop low-cost malaria drug..... Amgen's Bradway nets $13.65M in 2013, sans Onyx bonus..... Reckitt CFO: Spinoff of pharma unit a 'strong option'..... New report finds Bydureon safest of new class of diabetes drugs..... EMA warns Herceptin vials stolen in Italy spreading through EU..... GlaxoSmithKline's new diabetes med faces formidable GLP-1 foes..... Judge halts Massachusetts governor's ban on powerful Zogenix painkiller..... GlaxoSmithKline's Tanzeum gets FDA approval for type 2 diabetes treatment..... Actavis announces agreement related to Generess FE patent challenge litigation..... PanOptica raises $45m to finance clinical development of anti-VEGF eye drop for wet AMD..... Sanofi launches Probi Digestis in Korea..... Kineta and RLB Holdings announce new joint venture..... Akebia Therapeutics completes enrollment in its Phase IIb clinical study of AKB-6548..... IntelliCell BioSciences selects inVentiv Health Clinical as CRO for osteoarthritis IND..... Moberg Pharma to acquire global rights of bupivacaine from Oracain..... FDA extends market exclusivity of BioMarin's Phenylketonuria drug Kuvan for six months..... FDA accepts NDA for combination drug to treat type 2 diabetes..... BMV Medica to distribute Easton's Viorra in Mexico..... Roche cancer drugs Perjeta and Kadcyla drive strong Q1 results..... Novartis marks 235 admin jobs for deletion amid companywide restructuring..... New drugs are J&J's Q1 heroes, spurring pharma giant to hike 2014 forecast..... Boehringer Ingelheim revenue slide cushioned by Pradaxa sales jump..... Novartis' gain is consumers' $900M loss from stalled Ranbaxy generics..... Generics makers ask SCOTUS to let them proceed with Copaxone copies..... BMS files NDA to FDA for combination tablet to treat HIV-1..... Advaxis announces notice of allowance for two patent applications in Japan..... Depomed announces settlements with two Gralise ANDA filers..... Mast Therapeutics announces new data supporting MST-188 in sickle cell disease..... Surrey Clinical Research Centre signs five year agreement for OmniComm Systems' Promasys..... ProTrials completes significant Phase III clinical trial for new ophthalmic disease treatment..... FDA extends market exclusivity for BioMarin's Kuvan powder for oral solution and tablets..... Supreme enters into negotiations for an additional medical marijuana producing facility..... Federal judge enforces settlement agreement between Mylan and Endo Pharmaceuticals regarding generic Frova..... Enanta Pharmaceuticals to present detailed results from AbbVie?s pivotal Phase III SAPPHIRE-I study..... Dendreon to present long-term Phase II STAND study at EAU congress..... PolyTherics, MacroGenics extend deal to develop new antibody drug conjugates..... Bio-Rad completes acquisition of GnuBIO..... Ipsen presents first set of results on Phase III clinical study of Dysport..... Trinidad & Tobago Ministry of Health approves Janssen's prostate cancer drug Zytiga..... U.S. lawmakers join Lilly's attacks on Canada's patent attitude..... New attention disorder could equal a big new ADHD drug market. But is it legit?..... Polish prosecutors hit GlaxoSmithKline with third round of bribery charges..... Big Pharma tries to short-circuit France's move toward biosimilar substitution..... Lupin recalls more Suprax on purity problems, adding to Indian pharma's quality questions..... Novartis backs away from once-ambitious RNAi research..... Impax resubmits NDA for Parkinson's disease drug Rytary to US FDA..... Vyrix enters into agreement with Paladin for exclusive rights of Zertane in Canada..... FDA grants breakthrough therapy status for Celladon' heart failure treatment Mydicar..... Coronado starts investigator-initiated trial of TSO in pediatric patients with ASD..... Fate gets US patent for class of small molecule modulators of Rho-associated kinase..... Natco looking to block Indian patent for Gilead's Sovaldi..... PhRMA defends Gilead's pricey Sovaldi as docs look forward to more hep C choices..... Second drug spending report predicts double-digit increases coming..... EU takes up testosterone drug review on cardio worries..... Daiichi Sankyo lays out road map for Ranbaxy deal with Sun..... Vivus needs more than boardroom shuffling to keep up with Arena's Belviq..... Biotech stock tumble stumps analysts..... Theravance begins Phase IIb trial of TD-4208 to treat COPD..... American CryoStem and Rutgers University file joint patent on adipose-derived stem cell platform technology..... Assembly Pharmaceuticals, BioCrossroads to advance potentially curative therapy for chronic hepatitis b virus..... AbbVie announces availability of new advanced Parkinson's treatment in Canada..... Fate Therapeutics gets US patent for class of small molecule modulators of Rho-associated kinase..... Xencor receives milestone payment from Merck..... USPTO grants additional patent to BrainStorm for autologous stem cell technology..... Nuvilex engages ViruSure to establish cell banks for Phase IIb clinical trials in pancreatic cancer..... Alkermes' Phase III trial of schizophrenia drug aripiprazole lauroxil meets primary endpoint..... PuraMed advances development of first cannabinoid-based medicine..... Greenphire, ERT partner to strengthen patient compliance for clinical trials..... Clinipace to manage clinical programs on behalf of Karyopharm..... Eli Lilly, T1D Exchange enter research collaboration for new type 1 diabetes treatments..... French watchdogs raid Novartis, Roche in Lucentis antitrust probe..... UPDATED: Cochrane study: Stockpiling Tamiflu, Relenza was $2B 'thrown down the drain'..... Reckitt may top Novartis, Sanofi in $12B race for Merck consumer unit..... Hospira wins Herceptin patent suit in U.K., paving way for biosim..... AbbVie joins peers in Middle East with Saudi Arabia plans..... Hamburg to PhRMA: If you don't have quality, the rest doesn't matter..... Vetter launches new clinical syringe packages..... Vanda makes Hetlioz available in US to treat non-24-hour sleep-wake disorder..... Oricula Therapeutics secures initial funding from University of Washington..... First Aid Shot Therapy launches Upset Stomach..... DBV Technologies announces research collaboration agreement with CEA..... BioNeutral announces sales and distribution agreement with Menzer..... Critical Pharmaceuticals receives notice of allowance from USPTO for two hormone products..... Prothena starts Phase I trial of PRX002 to treat Parkinson's disease..... Neuland Labs opens new manufacturing facility in India..... DKSH, BMS extend partnership to provide commercial, distribution services in Asia..... Helix begins enrollment in Polish Phase I/II trial of lung cancer drug candidate..... Judge likely to boot Massachusetts ban of new opiate Zohydro..... Sources: Sun to phase out Ranbaxy brand in U.S...... Looking for pharma ads? Turn on the TV, not your smartphone..... SCOTUS asks generic Copaxone rivals for response to Teva's delay bid..... Express Scripts adds fuel to the fire in fight over Gilead Sciences' Sovaldi..... Novartis names two new leaders to growth drivers Alcon, Sandoz..... Boehringer's Pradaxa gets FDA approval for DVT, PE treatment..... Hyundai Hope On Wheels awards $2m research grant for Project:EveryChild..... EMA announces final steps for its clinical-trial data policy..... Elusys completes commercial manufacturing process validation for anthrax antitoxin ETI-204..... Seattle Genetics achieves milestones from Takeda for achieving first commercial sales of Adcetris..... TetraLogic Pharma to acquire Shape Pharma..... Genentech, PatientsLikeMe enters research collaboration for new oncology drugs..... Arno starts enrolling patients in Phase I/II trial of onapristone to treat prostate cancer..... TWi Pharma gets ANDA approval for Generic Procardia XL tablets in US..... Takeda to develop new ADC candidates using Mersana's Fleximer technology..... Sunovion introduces partial-onset seizures drug Aptiom in US..... Zogenix sues Massachusetts over ban on controversial painkiller Zohydro..... Teva entreats SCOTUS to block Copaxone generics till patent case wraps..... Express Scripts assembling anti-Sovaldi coalition to shut out Gilead hep C drug..... UPDATED: Boehringer's Pradaxa fights to regain ground with new clot-fighting approval..... Jury slaps Takeda, Lilly with massive $9B in damages in Actos cancer case..... J&J says BabyCenter beats Facebook and Twitter for intelligence-gathering..... Bristol-Myers files NDAs to FDA for daclatasvir and asunaprevir to treat hepatitis C..... Alnylam's McSwiggen patent upheld in European opposition proceedings..... BocaGreenMD launches generic version of vitaPearl..... EMA and TGA strengthen collaboration in area of orphan medicines..... Pacira Pharmaceuticals enters into co-production partnership with Patheon for Exparel..... Horizon Discovery launches new Genassist CRISPR and rAAV gene editing tools and services..... RSS NEWSFEED....

Welcome to
The Academy of
Pharmaceutical Sciences

The Academy of Pharmaceutical Sciences is the professional body for the Pharmaceutical Sciences in United Kingdom. A Pharmaceutical Scientist is an individual who contributes to bringing a new drug from concept through to a medicinal product. This includes, but is not exclusive to, individuals in academia, industry, regulation, clinical research and manufacturing.

The mission of the Academy of Pharmaceutical Sciences is to champion innovation and opportunity in Pharmaceutical Sciences for the delivery of medicines.

In order to achieve this mission, our aims are to:

Promote the Pharmaceutical Sciences to stakeholders to facilitate understanding and achieve engagement
Share learning, drive collaboration, partnership and innovation
Deliver insights into industry and academic roles for aspiring scientists

Latest News

The APS launches its new Parenterals Focus Group
FRIDAY, 11 APRIL 2014
The APS would like to announce the launch of its new Parenterals Focus Group. The group will provide a network for those interested in the science and technology of parenteral products and will aim to raise the profile of parenteral product development in the UK by stimulating scientific collaborations and providing a forum for information sharing and discussion of ‘hot topics’.. The group are interested in all aspects of parenteral product development but the steering committee have identified the following three themes to shape their initial programme over the coming year.. Meeting the needs of the user (medics, pharmacists, nurses and patients) – addressing current issues and preparing for the patient and products of the future. Alternative drying technologies for biotherapeutics and small molecules (in collaboration with the Biotherapeutics FG) . Challenges with the administration of parenteral products (‘in-use’ stability, giving set compatibility, interactions with co‑medications etc.) . The launch event for the Parenterals group will take place at this year’s UKPharmSci meeting in September. The group will be hosting a session on the afternoon of Tuesday September 9th entitled:. ‘Parenteral Drug Development: The Challenges of Adapting to Changing Patient Needs’ . During this session we will explore how the pharma industry can respond to the needs of the future, both in terms of the delivery of new types of parenteral medications, such as nanomedicines, as well as the ways in which parenteral products are administered e.g. home administration. The event will conclude with a roundtable discussion which we hope will help drive the future agenda of the group.. We are also planning a joint event with the Therapeutic Vaccines and Biologics Focus group – watch this space for further details.. You can stay up to date with the Parenterals Focus group developments by subscribing to our focus group from the ‘my account’ tab of the APS web-page. If you are interested in joining the steering committee, please contact Jo Broadhead or Jo Simmons by using the contact button on our focus group web-page.. http://www.apsgb.co.uk/focus_groups/overview.asp?TeamCode=PA25.

APS launch new Microbiology & Anti-Infectives Focus Group
FRIDAY, 28 MARCH 2014
The APS would like to announce the launch of its new Microbiology and Anti-infectives Focus Group. Details on its mission and how to get involved are given below:. . Scope . The Microbiology and Anti-infectives focus group is being launched in 2014 to provide a forum for the promotion of pharmaceutical microbiology and anti-infectives research and development within the academic, regulatory and industrial pharmaceutical sciences. The focus group is open to all members with an interest in pharmaceutical microbiology, antibiotic resistance, anti-infectives research and development, antibiotic innovation and regulatory developments. . . The main aims of this focus group are:. . To provide a forum for discussion of all aspects of pharmaceutical microbiology and anti-infectives research and development, that are of interest to members of the APS Seek to raise the profile of pharmaceutical microbiology and anti-infectives research across the pharmaceutical and allied sciences To underpin the importance of microbiology to the pharmaceutical sciences and innovation Collaborate and coordinate with other relevant organisations active in the field Provide continuing education for the membership, through annual symposia and focused meetings . Launch meeting. An initial meeting of the Microbiology & Anti-infectives focus group is planned for May 19th, School of Pharmacy, Queen’s University Belfast. At this meeting we will identify and prioritise the main areas of interest for the focus group with a view to organising an ongoing programme of 1-2 day meetings. At this meeting a steering group will be formed to develop the ongoing themes of the focus group activities.. . A programme is currently under development for PharmSci 2014 (8th – 10th September 2014, University of Hertfordshire); please consider submitting your abstracts for oral/poster presentations. Wiley-Blackwell have kindly agreed to sponsor a prize for the best poster in the Pharmaceutical Microbiology category, the winner will receive £100 and a copy of Hugo & Russell’s Pharmaceutical Microbiology 8th Edition.. . If you are interested in attending the launch meeting, becoming involved in the steering committee or joining the Microbiology & Anti-infectives Focus Group, please contact Brendan Gilmore via the FG website at the following link:. . http://www.apsgb.co.uk/focus_groups/overview.asp?TeamCode=AI22.

Progress within the IMI OrBiTo project
TUESDAY, 18 MARCH 2014
Predictive tools for oral biopharmaceutics GSK, Stevenage Tuesday 13th May 2014 The Innovative Medicines Initiative (IMI) ORBITO project is a pre-competitive collaboration between pharma, academia and specialist technology companies which aims to enhance our understanding of how orally-administered drugs are absorbed from the gastrointestinal tract and apply this knowledge to develop new in vitro tests and in silico models that will better predict the performance of oral formulations in patients (www.orbitoproject.eu). The OrBiTo project started in October 2012 and this is the first open meeting at which key progress will be shared with the wider scientific community. Professor Gordon Amidon will also present an update from his on-going research programme on assessing the bioperformance of oral drug products. This meeting is aimed at industrial and academic scientists working in the areas of biopharmaceutics, formulation design, regulatory CMC and analytical development. Scientists who are new to the area will also find the meeting useful for gaining a broad understanding of the key scientific and technical issues relevant to oral biopharmaceutics. Poster presentations are welcomed from all attendees. For more information, please visit us online at: http://www.apsgb.co.uk/events/20140513/

Skin Forum 2014, September 4th and 5th, Prague, Czech Republic.
MONDAY, 24 FEBRUARY 2014
. The final programme and registration forms for this year's joint Skin Forum - APV meeting are now available on the APV website at the following links: . . Programme and Fees. . http://www.apv-mainz.de/fileadmin/dateiablage/apv-mainz/Pdf_Programme/Skin_Forum_140227.pdf. . Abstract Submission. . http://www.apv-mainz.de/en/seminare/events/event/?seminar=35. . Programme and Fees. . http://www.apv-mainz.de/fileadmin/dateiablage/apv-mainz/Pdf_Programme/Skin_Forum_140227.pdf This year's programme features a dedicated industrial transdermal formulation session. For any queries related to the meeting please contact: majella.lane@btinternet.com . . . . . . . .

Upcoming Events

APS Amorphous by Design 2014
28 - 29 April 2014

Progress within the IMI OrBiTo project � predictive tools for oral biopharmaceutics
13 May 2014

APS Board Meeting
8 - 9 July 2014

APS PharmSci 2014
8 - 10 September 2014

APS Board Meeting
14 - 15 October 2014

Vacancies

View all Vacancies
Advertise your job vacancies

Following the extensive news coverage of the Heartbleed attack the Academy can confirm that it has NOT been affected and usernames and password used on this site have NOT been compromised.